3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
8
Triple Negative Breast Neoplasms
7
Nasopharyngeal Carcinoma
7
Breast Neoplasms
6
Esophageal Neoplasms
4
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Liver Neoplasms
3
Neoplasm Metastasis
2
Locally Advanced Rectal Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Adrenocortical Carcinoma
2
Unresectable Gallbladder Cancer
1
Turcot syndrome
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Non Squamous Non Small Cell Lung Cancer
1
Nasopharyngeal Neoplasms
1
Multiple Primary Lung Cancer
1
Melanoma
1
Locally Advanced or Metastatic Solid Tumors
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Her-2 Negative Breast Cancer
1
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
6
pembrolizumab
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
Drug Therapy
4
fludarabine
3
XELOX
3
Specimen Handling
3
Laparoscopy
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
camrelizumab
×
Clear all
NCT06215677
2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA
Recruiting
18 enrolled